Ace strengthens shareholder base

Attracting these investors specialised in the medical sector is an important step in realising Ace's ambition to further strengthen its position as an independent Dutch pharmaceutical company based in Zeewolde.

With this ambition, Ace is responding to a number of important trends in pharmaceutical healthcare.

Director Jan Verwaal: “Parts of the production chain are now organised close to home to guarantee the availability of crucial materials and medicines for the Netherlands and Europe, independent of (distant) foreign countries. In addition, we can respond to the great importance of drug rediscovery and help to reduce the increasing drug shortages.”

Director Jan Willem Popma: “The Covid-19 pandemic has clearly demonstrated the challenges and gaps in our sector for European countries. It makes our mission to make (and keep) scarce medicines available more current than ever. We want to respond even more emphatically to this and therefore grow strongly, both organically and through acquisitions in Europe. With the capital, know-how and broad (international) network of Gilde Buy-out, Gilde Healthcare, and our existing investor Quadrum Capital, we can do this in a socially responsible and financially sound manner.”

The existing management team will continue to manage Ace under the leadership of board members Jan Willem Popma and Jan Verwaal, and will continue as a major shareholder alongside Quadrum Capital.

About Ace Pharmaceuticals As an independent Dutch pharmaceutical company, Ace Pharmaceuticals has focused on the development, production and distribution of registered and unregistered medicines since 1990. With its activities Ace meets an essential social need; making and keeping scarce medication available to people for whom it is indispensable (e.g. through national named-patient programs). Since January 2020, Ace has also been supplying (compounded) pharmacy preparations via Ace Compounding and Ace Apotheek. The strong growth of recent years has led to the construction of a new in-house production facility at the head office in Zeewolde, which now employs 150 employees.

About Gilde Buy-Out and Gilde Healthcare Gilde Healthcare is a specialist independent European investment company focused on the healthcare sector with €1.4 billion under management. Through various funds, Gilde Healthcare participates in profitable healthcare companies, including healthcare providers, suppliers of medical products, pharmaceutical companies and service providers, preferably in the Benelux and German-speaking countries. It also targets high-growth innovative medical technology and pharmaceutical companies based in Europe and North America (https://gildehealthcare.com).

Gilde Buy Out Partners is a leading investment company in the European mid-market that focuses on investments in growth companies with their headquarters in the Benelux and the German-speaking countries in Europe. Gilde Buy Out Partners has more than €3.0 billion in funds under management and has offices in Utrecht, Brussels, Frankfurt and Zurich. Since its foundation in 1982, Gilde Buy Out Partners has invested in more than 250 companies to realize their growth ambitions (https://gilde.com).

About Quadrum Capital As a committed investment company, Quadrum Capital focuses on responsibly helping companies realize their growth ambitions. The contribution of high-quality management experience, a sharp vision, network, financial strength and focus on strategy and management forms the basis for this. Quadrum Capital is characterized by a strong regional anchoring, entrepreneurial mentality and no-nonsense approach and since its inception in 2012, Quadrum Capital has built up a broad portfolio of participations in various sectors, including in the medical & health domain (https://quadrum-capital.nl ).

Do you have questions? Please contact Ace Pharmaceuticals via our contact page.